sitaxsentan

Known as: N-(4-chloro-3-methyl-5-isoxazolyl)-2-((4,5-(methylenedioxy)-O-toly)acetyl)-3-thiophenesulfonamide, N-(4-chloro-3-methyl-5-isoxazolyl)-2-(3,4-(methylenedioxy)-6-methyl)phenylacetyl-3-thiophenesulfonamide, SITAXENTAN 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
BACKGROUND Despite advances in the management of pulmonary arterial hypertension (PAH), the mortality rate remains excessive… (More)
  • figure 1
  • table I
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2007
2007
BACKGROUND Bosentan, an oral ET(A)/ET(B) receptor antagonist, is approved for the treatment of pulmonary arterial hypertension… (More)
Is this relevant?
2007
2007
INTRODUCTION Endothelin receptor antagonism has become an important component in the treatment of pulmonary arterial hypertension… (More)
Is this relevant?
Review
2007
Review
2007
Angiogenesis is important in the pathogenesis of systemic inflammatory rheumatic diseases, a family of related disorders that… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
OBJECTIVES We sought to determine the optimal dose of the selective endothelin A (ET(A)) receptor antagonist sitaxsentan for the… (More)
  • figure 1
  • table 3
Is this relevant?
Review
2005
Review
2005
Sitaxsentan is an orally active, selective endothelin-A receptor antagonist that may benefit patients with pulmonary arterial… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Sitaxsentan may benefit patients with pulmonary arterial hypertension by blocking the vasoconstrictor effects of endothelin-A… (More)
Is this relevant?
2004
2004
Sitaxsentan, a highly selective endothelin-A (ET(A)) receptor antagonist (6500-fold more selective for ET(A) receptors than… (More)
Is this relevant?
Review
2004
Review
2004
Endothelin-1 (ET-1), a peptide produced primarily by vascular endothelial cells, was discovered in 1980 and it was characterized… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
STUDY OBJECTIVES To evaluate the safety and efficacy of sitaxsentan, an endothelin-A receptor antagonist, in a 12-week, open… (More)
Is this relevant?